Table 1 Subsequent anticancer therapy.

From: Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status

 

Patient group, n (%)

BRCAm (n = 145)

gBRCAm (n = 87)

sBRCAm (n = 55)

Non-BRCA HRRm (n = 33)

Received subsequent anticancer therapy

59 (40.7)

35 (40.2)

23 (41.8)

18 (54.5)

Platinum-based chemotherapya

48 (33.1)

29 (33.3)

18 (32.7)

15 (45.5)

 Carboplatin

41 (28.3)

24 (27.6)

16 (29.1)

12 (36.4)

 Cisplatin

11 (7.6)

8 (9.2)

3 (5.5)

5 (15.2)

 Oxaliplatin

1 (0.7)

0 (0.0)

1 (1.8)

0 (0.0)

Paclitaxel

36 (24.8)

22 (25.3)

14 (25.5)

13 (39.4)

Gemcitabine

21 (14.5)

10 (11.5)

10 (18.2)

5 (15.2)

Anthracyclines and related substances

19 (13.1)

13 (14.9)

6 (10.9)

8 (24.2)

 Doxorubicinb

18 (12.4)

12 (13.8)

6 (10.9)

8 (24.2)

 Epirubicin hydrochloride

1 (0.7)

1 (1.1)

0 (0.0)

0 (0.0)

Other antineoplastic agents

10 (6.9)

9 (10.3)

0 (0.0)

2 (6.1)

 Olaparib

5 (3.4)

4 (4.6)

0 (0.0)

0 (0.0)

 Topotecan

4 (2.8)

4 (4.6)

0 (0.0)

2 (6.1)

 Niraparib

1 (0.7)

1 (1.1)

0 (0.0)

1 (3.0)

Monoclonal antibodies

6 (4.1)

6 (6.9)

0 (0.0)

5 (15.2)

 Anetumab ravtansine

1 (0.7)

1 (1.1)

0 (0.0)

0 (0.0)

 Bevacizumabc

6 (4.1)

6 (6.9)

0 (0.0)

4 (12.1)

 MBG 453

1 (0.7)

1 (1.1)

0 (0.0)

0 (0.0)

 Pembrolizumab

0 (0.0)

0 (0.0)

0 (0.0)

1 (3.0)

  1. ATC anatomical therapeutic chemical, BRCAm BRCA1 and/or BRCA2 mutation, gBRCAm germline BRCAm, HRRm homologous recombination repair mutation, sBRCAm somatic BRCAm.
  2. Subsequent medications defined as medication taken after the end date of olaparib. ATC shown if received by ≥10% of patients in any cohort. Patients could receive one or more subsequent therapy.
  3. aPatients received carboplatin, cisplatin or oxaliplatin in combination with a nonplatinum agent.
  4. bDoxorubicin includes doxorubicin, doxorubicin hydrochloride, liposomal doxorubicin hydrochloride, pegylated liposomal doxorubicin and pegylated liposomal doxorubicin hydrochloride.
  5. cPatients received bevacizumab in combination with chemotherapy (n = 8) or other agents (n = 2).
Back to article page